Description

 

Join us in London this February to connect with those trailblazing the next wave of CAR and TCR based approaches from pre-clinical development with in vivo engineering and regulatory fast-track strategies to streamlined analytics and automation to make CAR and TCR therapies better, and faster.

Take advantage of cutting-edge innovation from global biopharma leaders in cell armouring, combination approaches and multiplexing gene engineering to improve cell durability and trafficking across allogeneic and solid tumour indications, and leave understanding the technical strategies to build automated, closed-system manufacturing processes to ensure vein to vein time is less than a week.

Promising data-driven case studies outlining next generation product design, clinical trial set-up and manufacturing processes, this meeting is your go-to to comprehensively assess the emerging improvements of CAR and TCR based therapies.

Full agenda: https://ter.li/bkn23j

URLs:
Brochure: https://go.evvnt.com/1401489-0?pid=10007
Website: https://go.evvnt.com/1401489-3?pid=10007

Prices:
Drug Developer – Conference + Workshop Day (Standard Rate – Earlybird Discounts Available): GBP 3299.00,
Drug Developer – Conference Only (Standard Rate – Earlybird Discounts Available): GBP 2499.00,
Academics and Start Ups – Conference + Workshop Day (Standard Rate – Earlybird Discounts Available): GBP 2599.00,
Academics and Start Ups – Conference Only (Standard Rate – Earlybird Discounts Available): GBP 1999.00,
Standard – Conference + Workshop Day (Standard Rate – Earlybird Discounts Available): GBP 4599.00,
Standard – Conference Only (Standard Rate – Earlybird Discounts Available): GBP 3499.00

Speakers: Blake Aftab, Chief Scientific Officer, Adicet Bio, Sara Padrell, Director, Business Development, Europe, Akron Biotech, Cecile Bauche, Chief Executive Officer and Chief Scientific Officer, Alaya.bio, Reagan Jarvis, Co-Founder and Chief Executive Officer, Anocca, Sven Kili, Chief Executive Officer, Antion Biosciences, Nick Haining, Co-Founder and Chief Scientific Officer, Arsenal Bio, Jakob Dupont, Executive Vice President and Global Head of R and D, Atara Biotherapeutics, Flavio Lima Bianchi, Beacon Adoptive Cell Analyst, Beacon Targeted Therapies, Jiangtao Ren, Co-Founder and Chief Scientific Officer, Bioheng Biotech, Samik Basu, Chief Scientific Officer, Cabaletta Bio, Adrian Bot, Chief Scientific Officer and Executive Vice President of R and D, Capstan Therapeutics, Ann Ager, Professor, Cellular Immunity and Immunotherapy, Cardiff University, Andy Stewart, Senior Director, Research, Cartesian Therapeutics, Laurent Poirot, Senior Vice President, Immunology, Cellectis, Daniel Teper, Chief Executive Officer, Cytovia Therapeutics, Jamal El-Mosleh, Chief Executive Officer, Elicera Therapeutics, Kevin Pojasek, President and Chief Executive Officer, Enara Bio, Joseph Dukes, Head of Research, Enara Bio, Sophie Papa, Chief Medical Officer, Enara Bio, Alan Baer, Staff Fellow, Division of Cellular and Gene Therapies, CBER, FDA, Manel Juan, Head of Immunology Service, Hospital Clinic Of Barcelona, Cedrik Britten, Chief Medical Officer, Immatics, Andrea Mayer- Mokler, Senior Director, Global Head Clinical Sciences, Immatics, Mamta Kalra, Director, CMC and Process Development, Immatics, Bakul Gupta, Chief Executive Officer, ImmTune Therapies, Sarbari Ghosh, Scientist, Process and Analytical Development, Immuneel Therapeutics, Rohan Kamat, Head of Process and Analytical Development, Immuneel Therapeutics, Lawrence Lamb, Executive Vice President and Chief Scientific Officer, IN8Bio, Frederik De Vos, Senior Director, CAR-T Quality, Johnson and Johnson, Hemant Dhamne, Head, Process Development, Gene Therapy Vector Facility, King’s College London, Reuben Benjamin, Consultant Haematologist and Honorary Clinical Senior Lecturer, King’s College London, Rhine Shen, Senior Director, Head of Clinical Pharmacology, Kite Pharma: A Gilead Company, Vaishali Shukla, Vice President, Quality, Commercial Manufacturing, Kite Pharma: A Gilead Company, John Maher, Chief Scientific Officer, Leucid Bio, Gary Lee, Chief Scientific Officer, Lyell Immunopharma, Dolores Schendel, Chief Executive Officer and Chief Scientific Officer, Medigene, Amir Hefni, Vice President, Global Head of Cell and Gene Therapy, Novartis, Miriam Fuchs, Executive Director, Global Therapeutic Area Lead, Regulatory Affairs, Cell and Gene Therapy, Novartis, Ozlem Anak, Vice President, Global Programme Head, Cell and Gene, Novartis, Houra Loghami, Senior Scientist, Translational and Oncology, Oncolytics Biotech, Vered Caplan, Chief Executive Officer, Orgenesis, Dan Shelly, Vice President, Business Development and Alliances, Prescient Therapeutics, David DiLillo, Director, Immuno- Oncology, Regeneron Pharmaceuticals, Aaron Foster, Vice President, Immunology, Sana Biotechnology, Geoffrey Hodge, Chief Executive Officer, SOTIO Biotech US, Bryan Kobel, Chief Executive Officer, TC BioPharm, Thomas Lars Andresen, Chief Executive Officer, T-Cypher Bio, Mindy Miller, Lead Research Scientist, R and D, Terumo Blood and Cell Technologies, Renu Balyan, Manager, Diagnostics and Biomarker Lead, Clinical Development, Tessa Therapeutics, James Keck, Senior Director, Innovation and Product Development, The Jackson Laboratory, Mikhail Steklov, Team Lead, Cell Fitness Group, T-Knife Therapeutics, Deyaa Adib, Chief Medical Officer, Triumvira Immunologics, Aaron Sato, Chief Scientific Officer, Twist Bioscience, Qasim Rafiq, Associate Professor, Cell and Gene Therapy Bioprocessing, University College London, Kenneth Jacobs, Vice President, Pharmacovigilance and Clinical Development, Wugen, Luise Weigand, Head of Research, Zelluna Immunotherapy